Telehealth Addiction Treatment Statistics 2026: Post-Pandemic Numbers, the New DEA Rules, and What Virtual Care Data Really Shows

Telehealth moved from the edges of addiction medicine to its center in about five years, and the numbers documenting that shift are scattered across federal surveys, Medicare claims studies, and a fast-moving regulatory docket. This page gathers the current statistics in one place: facility adoption, the strongest outcome studies, the DEA rules governing telemedicine prescribing through 2026, and the New Hampshire and Massachusetts picture. Every figure carries its year and a link to the primary source, and where a widely repeated number is outdated or misattributed, we say so explicitly. Data were last verified in July 2026.

Key numbers at a glance

• 80.4 percent of the 15,953 US substance use treatment facilities used telemedicine or telehealth in 2024, per the SAMHSA N-SUMHSS 2024 survey (2024 data).
• That share was 27.5 percent in 2019 and 58.6 percent in 2020, per SAMHSA's telemedicine services report (2021).
• Medicare beneficiaries with opioid use disorder who received telehealth services had 27 percent higher odds of staying on medication for opioid use disorder (aOR 1.27) and lower odds of a medically treated overdose (aOR 0.67), per JAMA Psychiatry (2022).
• The same research group linked opioid-related telehealth to 33 percent lower odds of fatal overdose (aOR 0.67, 95 percent CI 0.48 to 0.92), per JAMA Psychiatry (2023).
• In a virtual intensive outpatient cohort of 4,724 adults, 79.9 percent were still engaged at 30 days and 50.4 percent at 90 days, per Healthcare (2024).
• Among surveyed intensive outpatient patients, 70.8 percent (680 of the 960 answering) reported continuous abstinence three months after discharge, with no significant difference between in-person, virtual, and hybrid formats, per JMIR Mental Health (2022).
• DEA telemedicine flexibilities for prescribing controlled medications now run through December 31, 2026, per the Federal Register (2025).
• 37.0 percent of US adults used telemedicine in 2021, falling to 30.1 percent in 2022, per NCHS Data Brief 445 (2022) and NCHS report 205 (2024).
• More than 2.9 million veterans took part in over 14.6 million VA telehealth episodes in fiscal 2025, per VA News (2026).
• New Hampshire's provisional 12-month drug overdose deaths fell from 430 (ending December 2023) to 282 (ending December 2024), and Massachusetts fell from 2,380 to 1,598 over the same windows, per CDC provisional data (2026).

How many addiction treatment facilities offer telehealth?

The authoritative count comes from SAMHSA's National Substance Use and Mental Health Services Survey (N-SUMHSS), an annual census-style survey of every known substance use and mental health treatment facility in the country. In 2021 it replaced two older surveys, including the N-SSATS series that most older telehealth statistics come from.

The current numbers, from Table SU19 of each year's detailed tables:

• 2021: 10,105 of 14,010 substance use treatment facilities (72.1 percent) used telemedicine or telehealth (N-SUMHSS 2021).
• 2022: 11,359 of 14,854 facilities (76.5 percent) (N-SUMHSS 2022).
• 2023: 11,616 of 14,620 facilities (79.5 percent) (N-SUMHSS 2023).
• 2024: 12,825 of 15,953 facilities (80.4 percent) (N-SUMHSS 2024), the newest data available as of mid-2026.

A correction on the "27.5 percent then, 60 percent now" pair

Many articles about online addiction treatment still cite a pair of adoption figures: 27.5 percent of facilities in 2019 versus "over 60 percent" today. Both numbers are real, but neither is current. They come from SAMHSA's December 2021 telemedicine report, which drew on the retired N-SSATS survey: 25.7 percent of facilities offered telemedicine in 2015, 27.5 percent in 2019, and 58.6 percent in 2020, the first pandemic year. The "over 60 percent" figure is, in other words, 2020 data. The current number is 80.4 percent as of 2024, and it has risen every year since the pandemic rather than receding. Telehealth in addiction care outlasted the emergency that created it.

Does telehealth addiction treatment work? The Medicare evidence

The most rigorous effectiveness data so far come from two federal cohort studies of Medicare claims, led by Christopher M. Jones and colleagues from CDC, CMS, and NIDA, published in JAMA Psychiatry.

The 2022 study followed two national cohorts of Medicare beneficiaries starting opioid use disorder care: 105,240 people before the pandemic (September 2018 to February 2020) and 70,538 people during it (September 2019 to February 2021). Receipt of opioid-related telehealth jumped from 0.6 percent of the prepandemic cohort to 19.6 percent of the pandemic cohort. Within the pandemic cohort, people who received telehealth services were more likely to stay on medications for opioid use disorder on 80 percent or more of eligible days (adjusted odds ratio 1.27, 95 percent CI 1.14 to 1.41) and had lower odds of a medically treated overdose (adjusted odds ratio 0.67, 95 percent CI 0.63 to 0.71).

The 2023 follow-up linked the same cohorts to National Death Index records to study fatal overdose, which occurred at a rate of 5.1 per 1,000 beneficiaries in the pandemic cohort. Receiving opioid-related telehealth was associated with 33 percent lower odds of fatal overdose (adjusted odds ratio 0.67, 95 percent CI 0.48 to 0.92). Medications for opioid use disorder showed the same protective direction: 59 percent lower odds with treatment at an opioid treatment program (aOR 0.41) and 38 percent lower odds with office-based buprenorphine (aOR 0.62).

These are observational studies, so they show strong associations rather than proof of cause and effect. But they are large, national, consistent with each other, and they measure the outcomes that matter most: staying in treatment and staying alive.

A correction on the "56, 67, and 43 percent" figures

A set of percentages circulates in articles about online addiction treatment claiming web-based programs reduce substance use by 56 percent, increase abstinence by 67 percent, or cut dropout by 43 percent. Those figures trace back to research on self-guided web interventions for behavioral addictions such as problem gambling and internet gaming, not to clinician-delivered treatment for substance use disorders. Applying them to virtual SUD treatment misstates what was studied. The Medicare cohort studies above, and the intensive outpatient studies below, are the evidence that actually addresses the question.

"What the retention findings tell me as a clinician is that the barrier telehealth removes is often the barrier that was breaking treatment: the drive, the time off work, the childcare. When someone can keep every appointment, the medicine and the therapy get a fair chance to work. The assessment question is never whether virtual care is good or bad, it is whether this patient, at this point in their illness, can be safely and effectively treated through a screen."

Dr. Richard Marasa, Medical Director, Clear Steps Recovery

Virtual IOP outcomes: what retention and completion data show

An intensive outpatient program (IOP) delivers structured therapy several days per week while the person keeps living at home, which makes it the level of care most naturally suited to virtual delivery. Two peer-reviewed studies anchor what is currently known about virtual IOP outcomes.

A 2024 retrospective cohort study in Healthcare followed 4,724 adults in a fully virtual, US-wide substance use IOP. Engagement held at 79.9 percent after 30 days, 63.0 percent at 60 days, 50.4 percent at 90 days, and 39.9 percent at 120 days, with an average enrollment of 131 days. During care, 91 percent of patients achieved at least 30 consecutive days of abstinence. The authors note these engagement figures compare favorably with published estimates for conventional in-person IOP care, which cluster between 50 and 68 percent at 30 days.

A 2022 study in JMIR Mental Health examined 3,642 IOP patients at a large nonprofit treatment organization whose programming shifted across in-person, virtual, and hybrid formats during the pandemic. Among the 1,060 patients who completed surveys three months after discharge, 70.8 percent of those answering the abstinence question (680 of 960) reported continuous abstinence, and the study detected no significant differences in abstinence by delivery format. The honest caveat: only 29.1 percent of discharged patients answered the follow-up survey, so the abstinence figure describes survey respondents, not everyone treated.

Where the honest ranges come from

A "50 to 70 percent success rate" for virtual IOP appears on many pages with no citation, no metric, and no time point. Numbers in that range do exist in the literature, but they mean different things: roughly 50 percent engagement at 90 days in the 2024 cohort, or 70.8 percent self-reported abstinence at three months among survey responders in the 2022 study. When you see a success rate quoted for any program, the useful question is always: percent of whom, doing what, measured when?

What is not yet proven matters too. No large randomized trial has assigned comparable patients to virtual versus in-person IOP, so claims that one format is superior outrun the data. The defensible 2026 statement is that observational outcomes look comparable, and that retention, the strongest modifiable predictor of recovery, may favor virtual delivery when the main obstacle is logistics. For why retention matters so much, see our companion review of relapse statistics.

"Attendance is not the same as engagement, and a screen makes that distinction sharper. What keeps people present week over week is the same thing that works in a physical room: being known. Small groups where absence is noticed, a counselor who follows up the same day, family looped in early. We built our virtual intensive outpatient care around those touchpoints precisely because accountability is the first thing to erode online if no one is watching for it."

Dr. Richard Marasa, Medical Director, Clear Steps Recovery

For a plain-language walkthrough of how a virtual IOP day actually runs, see our overview of virtual IOP care.

The DEA telemedicine rules, 2020 to 2026

The adoption numbers above rest on a regulatory story, and it is the part of the telehealth picture that changes fastest. Under the Ryan Haight Act of 2008, prescribing controlled medications such as buprenorphine normally requires an in-person medical evaluation first. When the COVID-19 public health emergency was declared in early 2020, DEA activated the law's telemedicine exception nationwide, letting clinicians start patients on buprenorphine by video or phone without a prior in-person exam.

That emergency posture has since been extended four times while DEA writes permanent rules: in May 2023, October 2023 (through December 31, 2024), November 2024 (through December 31, 2025), and most recently the fourth temporary extension of December 31, 2025, which keeps the flexibilities in place through December 31, 2026. The full dated timeline appears in the table below.

Alongside the extensions, DEA and HHS published two January 17, 2025 rulemakings. The Expansion of Buprenorphine Treatment via Telemedicine Encounter is a final rule; after two effective-date delays under the January 2025 regulatory freeze (finalized at December 31, 2025), it is now in effect and permanently allows an initial six-month supply of buprenorphine to be prescribed through telemedicine, including audio-only encounters, after the prescriber reviews the state prescription drug monitoring program. The companion Special Registrations for Telemedicine proposed rule, which would create a permanent registration framework for telemedicine prescribing, closed for comment on March 18, 2025 and had not been finalized as of July 2026.

The post-PHE synthesis table: rules, adoption, and state policy in one place

No single federal page pairs the rule timeline with the adoption data and the state Medicaid picture, so we compiled one. Every cell links to a primary source verified live in July 2026.

Telemedicine buprenorphine and medication-assisted treatment

For opioid use disorder specifically, the regulatory changes above matter because they govern medication access. Buprenorphine, one of the FDA-approved medications for opioid use disorder, can now be started through a telemedicine encounter, including a phone call, with the initial six months of prescriptions allowed before an in-person visit is required for further audio-only prescribing, under the final rule effective December 31, 2025.

The outcome data reviewed earlier is what justified that permanence. In the 2023 Medicare analysis, office-based buprenorphine was associated with 38 percent lower odds of fatal overdose, and telehealth was one of the main doors through which pandemic-era patients reached it. In practical terms, telemedicine turned medication initiation from an appointment problem into a same-week possibility for many people.

At Clear Steps Recovery, medication-assisted treatment combines these medications with counseling and is coordinated within outpatient levels of care. When someone needs medically supervised withdrawal before starting, we arrange that through referral to trusted detox partners rather than on site, then continue care once stabilization is complete.

Who uses telehealth for behavioral health?

The national baseline comes from the CDC's National Health Interview Survey. In 2021, 37.0 percent of US adults had used telemedicine in the previous 12 months (NCHS Data Brief 445, 2022). Use was higher among women than men (42.0 versus 31.7 percent), climbed with education, from 28.7 percent among adults without a high school diploma to 43.2 percent among college graduates, and rose with family income, from 33.1 percent of adults below the federal poverty line to 40.7 percent at four times the poverty level or higher. Two patterns matter for addiction care planning:

• The rural gap. Telemedicine use fell steadily with rurality, from 40.3 percent of adults in the central counties of large metropolitan areas to 27.5 percent in the most rural, noncore counties (NCHS, 2021 data). The people with the longest drives to treatment are also the least likely to have used virtual care, a gap tied partly to broadband access across rural northern New England.
• The post-pandemic settling. Overall adult telemedicine use declined to 30.1 percent in 2022 (NCHS, 2024) as routine medicine returned to offices. Addiction treatment moved the opposite way: facility telehealth use kept climbing, from 72.1 percent in 2021 to 80.4 percent in 2024 (N-SUMHSS). Virtual delivery is becoming more embedded in substance use care even as it recedes elsewhere in medicine.

Veterans and VA telehealth for substance use

The Department of Veterans Affairs runs the largest telehealth operation in American health care. In fiscal year 2025, more than 2.9 million veterans took part in over 14.6 million telehealth episodes of care, a 10 percent increase over the prior year, and 91.7 percent of veterans who used telehealth reported being satisfied with it (VA News, January 2026). VA's telehealth services hub spans home-based video care, including mental health and substance use services.

The research adds a caution flag for veterans who need dual-track care. A study of rural veterans in VA care from fiscal 2016 through 2019 found that those with co-occurring anxiety and alcohol use disorder received a smaller share of their mental health care by video (about 14 percent of visits) than veterans with anxiety alone (about 24 percent), and their telehealth use grew more slowly (Journal of Technology in Behavioral Science, 2020). Telehealth reaches veterans well overall; the most clinically complex cases still lag.

For veterans in New Hampshire and Massachusetts, Clear Steps Recovery participates in the VA Community Care Network, which lets eligible veterans use community providers when VA care is distant or delayed. Our guide to veterans' addiction treatment through VA Community Care explains eligibility and referrals in detail.

Dual diagnosis care through telehealth

Most people entering addiction treatment also manage a mental health condition, most commonly depression or anxiety, and virtual programs have to treat both at once to work. The direct evidence on virtual mental health care is reassuring: a 2022 systematic review and meta-analysis in Psychological Medicine covering 9 randomized trials and 1,268 patients found no differences between telehealth and face-to-face care in depression severity at the end of treatment.

For combined substance use and mental health treatment delivered virtually, the evidence base is younger. SAMHSA's evidence-based resource guide on telehealth for serious mental illness and substance use disorders (2021) concluded telehealth can effectively support assessment, therapy, and medication management across both condition types, while calling for more integrated-treatment research. The rural-veterans study above shows why this matters: people with co-occurring conditions are precisely the group whose virtual engagement needs deliberate clinical attention rather than assumption.

How integrated treatment for depression, anxiety, and addiction works in practice, virtual or in person, is covered in our guide to dual diagnosis treatment.

Cost, insurance, and telehealth parity in 2026

Coverage stopped being the main obstacle several policy cycles ago, though details differ by payer:

• Medicare permanently covers behavioral and mental health telehealth, with no geographic restriction, the home allowed as an originating site, and audio-only visits permitted for behavioral care, per HHS's post-PHE policy summary.
• New Hampshire Medicaid must, by statute, cover and reimburse telehealth services "on the same basis" as in-person care, across "all modes of telehealth, including video and audio, audio-only, or other electronic media" (RSA 167:4-d). The statute also ties telehealth medication-assisted treatment into the state's Doorway system, requiring provider notification to the patient's regional Doorway with consent.
• MassHealth made its pandemic-era telehealth coverage permanent through All Provider Bulletin 374 (2023): covered services may be delivered by live video, audio-only, or asynchronous telehealth, with behavioral health services reimbursed at parity with in-person rates.

The two-state comparison is unusually favorable: a person in Londonderry and a person in Needham both have Medicaid programs that treat a virtual counseling session like an office visit, including by phone. Commercial plans in both states broadly cover behavioral telehealth too, with varying cost-sharing. Our insurance guides for New Hampshire and Massachusetts explain how to verify benefits before starting.

Telehealth and addiction treatment in New England

The regional context for virtual care is a treatment landscape that is improving but thin in exactly the places telehealth serves best.

The overdose trend has turned. CDC provisional data show New Hampshire's 12-month drug overdose deaths falling from 430 (period ending December 2023) to 282 (ending December 2024), a roughly 34 percent decline, with the provisional count for the 12 months ending January 2026 at 266. Massachusetts fell from 2,380 to 1,598 over the same December-to-December windows, about 33 percent, with a provisional 1,324 for the period ending January 2026 (CDC Vital Statistics Rapid Release, 2026; recent months remain provisional and may be revised upward). State-level detail lives with the NH Drug Monitoring Initiative and the Massachusetts DPH current opioid statistics.

Both states' treatment systems have gone virtual. In the 2024 N-SUMHSS state profiles, 77 of New Hampshire's 94 substance use treatment facilities (81.9 percent) and 343 of Massachusetts' 429 facilities (80.0 percent) reported frequently using telemedicine or telehealth in opioid use disorder care, both at or above the national rate.

Capacity is the constraint telehealth eases. New Hampshire has fewer than 100 treatment facilities for the entire state, and the NCHS urbanization data above show rural residents are the least likely to have used telemedicine. For a shift worker in the Manchester-Londonderry corridor or a parent in the Boston suburbs around Needham, a virtual IOP means evening group therapy without a commute, often the difference between finishing a program and quietly dropping out. That is a logistics point, not a claim of clinical superiority, and the right level of care still depends on an individual assessment.

When telehealth is not the right starting point

An honest statistics page has to mark the boundaries of its own good news. Telehealth is a delivery method, not a level of care, and there are situations where the data and standard clinical practice point away from starting virtually:

• Withdrawal risk comes first. Alcohol, benzodiazepine, and heavy opioid withdrawal can be medically dangerous and cannot be managed over video. When an assessment finds significant withdrawal risk, the safe sequence is a referral to a medically supervised detox program first, with outpatient or virtual care beginning after stabilization. Clear Steps Recovery arranges detox exclusively by referral to partner facilities, not on site.
• Higher levels of care exist for a reason. Repeated recent overdoses, an unstable psychiatric condition, or a home environment saturated with substance use may call for residential care or daily in-person structure first.
• The technology floor is real. SAMHSA's telehealth resource guide (2021) flags privacy and connectivity as core feasibility checks, and the NCHS rural-use gap above shows this is not a hypothetical barrier in northern New England.
• Engagement needs monitoring. Every virtual IOP study shows engagement declining over time. Good programs treat early missed sessions as a clinical signal, not an administrative one.

"Telehealth widens the front door, it does not replace the assessment behind it. The first questions I ask are about withdrawal risk, because a person who needs medically supervised detox needs that arranged first, through a referral to the right facility, before any outpatient plan makes sense. When we make that referral, we stay in the loop and we schedule the follow-up before the person leaves the conversation, so the handoff is a bridge rather than a gap."

Dr. Richard Marasa, Medical Director, Clear Steps Recovery

If you are unsure which starting point fits, a confidential phone assessment with our admissions team at (603) 769-8981 can sort it out quickly, and if what you need is a detox referral or a higher level of care elsewhere, we will say so plainly. In immediate crisis, call or text 988, or reach the SAMHSA National Helpline at 1-800-662-HELP (4357).

How we sourced these numbers

Every statistic on this page comes from a primary source: SAMHSA's N-SUMHSS facility survey and its predecessor reports, the Federal Register, peer-reviewed journals, CDC's National Center for Health Statistics, the Department of Veterans Affairs, and New Hampshire and Massachusetts state government sources. Facility adoption figures come from Table SU19 of each survey year's detailed tables and the 2024 state profiles. No figures were drawn from marketing pages or other treatment providers' websites, and where a commonly cited number is outdated or misattributed, we identified the original source and the correction. Overdose figures labeled provisional come from CDC's Vital Statistics Rapid Release and are subject to revision. All source links were verified live on July 3, 2026, this page's last-reviewed date. We will re-verify when SAMHSA releases 2025 N-SUMHSS data and when DEA finalizes the special registration rule.